All posts from Zacks
Zacks in Our Research. Your Success.,

Endocyte (ECYT) Reports a Narrower Q1 Loss

West Lafayette, IN-based Endocyte, Inc ECYT is a development-stage biopharmaceutical company, focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market. The company uses its proprietary technology to create small-molecule drug conjugates (SMDCs) and companion imaging agents for the SMDCs to identify patients whose disease over-expresses the target of the therapy, and are thereby likely to benefit from treatment.

Endocyte aims to develop targeted SMDCs with a shorter half-life, which may help the company gain an edge over existing therapies.The company continues to progress on its pipeline, which comprises vintafolide (non-small cell lung cancer), EC1456 (advanced solid tumors) and EC1169 (recurrent prostate cancer).

Endocyte has a mixed track record. The company has beaten estimates in three of the last four quarters, with a positive average earnings surprise of 8.57%.

Currently, Endocyte has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share.

Revenue: The company earned collaboration revenue of $12,000.

Check back later for our full write up on this Endocyte earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. blog">Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
To read this article on click here.